1100 13th Street, NW, Suite 750Washington, DC 20005202.887.6400Customer Service: 800.544.0155
All Contents © 2019The Kiplinger Washington Editors
Gilead Sciences stock was selling for a mere 7 times estimated 2016 earnings when I snapped up 150 shares.
I've been asking myself whether American Capital's drop represents a buying opportunity or a warning that something is amiss.
A growth-oriented manager tells why his fund has excelled, and a bargain hunter explains why his fund has lagged.
More Investing News »